Abstracts tagged "Rheumatology"

Abstract Number: 3027 • 2016 ACR/ARHP Annual Meeting
Herpes Zoster in Patients with Moderate to Severe Rheumatoid Arthritis Treated with Baricitinib
Kevin L. Winthrop¹, Stephen Lindsey², Michael Weinblatt³, Tsutomu Takeuchi⁴, David Hyslop⁵, Maher Issa⁵, Lei Chen⁵, John Bradley⁵, Christina Dickson⁵ and Roy Fleischmann⁶, ¹Oregon Health and Sciences University, Portland, OR, ²Ochsner Medical Center, Baton Rouge, LA, ³Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Compared to the general population, RA patients (pts) have an increased risk of herpes zoster (HZ) due to their disease and various DMARD therapies…
Abstract Number: 1142 • 2016 ACR/ARHP Annual Meeting
Impact of a Student Led Rheumatology Interest Group on Medical Student Interest in Rheumatology
Timothy Brady¹, Michael Sheppard², N. Andrew LaCombe², Sonia Silinsky Krupnikova², Nora Taylor², Pragya Singh¹, Sean McNish¹ and Victoria K. Shanmugam¹, ¹Division of Rheumatology, The George Washington University, Washington, DC, ²The George Washington University, Washington, DC
Impact of a Student Led Rheumatology Interest Group on Medical Student Interest in Rheumatology Background/Purpose: Based on data from the 2005 Rheumatology Workforce Study the…
Abstract Number: 1584 • 2016 ACR/ARHP Annual Meeting
Bari-00074565
C. Steven Ernest II, Lisa O’Brien, David Radtke, Michael Heathman, Terence Rooney, William Macias and Xin Zhang, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib is an oral selective inhibitor of Janus kinases 1/2 and has demonstrated dose-dependent efficacy in moderate-to-severe RA patients who were DMARD-naïve or with…
Abstract Number: 1585 • 2016 ACR/ARHP Annual Meeting
Previous Use of Conventional Disease-Modifying Antirheumatic Drugs and Response to Baricitinib
Arthur F. Kavanaugh¹, Ronald F. van Vollenhoven², David Muram³, Jahangir Alam³, Vipin Arora³, Ana Luisa de Macedo Pinto Correia³, Inmaculada de la Torre^3,4 and James R. O'Dell⁵, ¹UC San Diego School of Medicine, La Jolla, CA, ²Rheumatology Unit, Karolinska University Hospital, Solna, Sweden, ³Eli Lilly and Company, Indianapolis, IN, ⁴Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, ⁵Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Baricitinib (BARI), an oral JAK1/JAK2 inhibitor, is in development for patients (pts) with moderate to severe RA.1,2 The purpose of this post hoc analysis…
Abstract Number: 1586 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials
Alvin F. Wells¹, Maria Greenwald², John D. Bradley³, Jahangir Alam³, Vipin K. Arora³ and Cynthia E. Kartman³, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²Desert Medical Advances, Palm Desert, CA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari), an oral selective JAK1 and JAK2 inhibitor, has been shown to be safe and efficacious compared to placebo (PBO) in two Phase…
Abstract Number: 1590 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis
Roy Fleischmann¹, Jahangir Alam², Vipin Arora², John D. Bradley², Douglas E. Schlichting² and David Muram², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari), an oral JAK1 and JAK2 inhibitor, is in development for patients (pts) with moderate to severe RA. Drug-related problems are common in…
Abstract Number: 1591 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis
Peter C. Taylor¹, Edward Keystone², Robert Ortmann³, Maher Issa³, Li Xie³, David Muram³, John D. Bradley³, Stephanie de Bono³, Terence Rooney³ and Yoshiya Tanaka⁴, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor under investigation for the treatment of patients (pts) with moderate to severe RA.1-2 In the 52-week Phase…
Abstract Number: 2717 • 2014 ACR/ARHP Annual Meeting
Comparison of PROMIS^® survey Between Scleroderma Patients in an Academic Center and Patient-Based Scleroderma Foundations
Vivek Nagaraja¹, Veronica Berrocal², Kerri Connolly³, Ann Kennedy⁴, Daniela Seelmann⁵ and Dinesh Khanna¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI, ³Scleroderma Foundation, Boston, MA, ⁴Federation of European Scleroderma Associations, Tournai, Belgium, ⁵Universidad de Los Andes, Santiago, Chile
Background/Purpose The National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS®) roadmap initiative is a cooperative research program designed to develop, evaluate, and standardize…
Abstract Number: 1151 • 2014 ACR/ARHP Annual Meeting
Barriers and Facilitators of a Career in Research Among Rheumatologists in the United States
Alexis Ogdie¹, Sheila Angeles-Han², Una Makris³, Amanda Nelson⁴, Ami Shah⁵, Yihui Jiang⁶, J. Michelle Kahlenberg⁷, Eyal Muscal⁸, Flavia V. Castelino⁹, Amit Golding¹⁰ and Alfred Kim¹¹, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Pediatrics, Emory University School of Medicine, Atlanta, GA, ³Rheumatology, Dallas VA Medical Ctr, Dallas, TX, ⁴5) Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Division of Rheumatology, John Hopkins University, Baltimore, MD, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁷Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁸Rheumatology, Texas Children's Hospital, Houston, TX, ⁹Rheumatology, Massachusetts General Hospital, Boston, MA, ¹⁰Medicine/Rheumatology and Clinical Immunology, Baltimore VA and University of Maryland School of Medicine, Baltimore, MD, ¹¹Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO
Background/Purpose: Development of young rheumatology investigators is critical to the future of rheumatology. Beyond funding, the specific barriers to maintaining a career in rheumatology research…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].